Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 9/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL340885 | 1.00 | MALT1 (0.35) | MALT1DHODHTRPV1TRPA1NOTUM | |
| SCHEMBL341062 | 0.90 | TRPV1 (0.33) | MALT1TRPV1TRPA1 | |
| SCHEMBL341061 | 0.90 | TRPV1 (0.33) | MALT1TRPV1TRPA1 | |
| SCHEMBL44772 | 0.84 | TRPA1 (0.35) | MALT1DHODHTRPV1TRPA1 | |
| SCHEMBL45070 | 0.83 | MALT1 (0.35) | MALT1DHODHTRPV1TRPA1NOTUM | |
| SCHEMBL339427 | 0.83 | MALT1 (0.35) | MALT1DHODHTRPV1TRPA1NOTUM | |
| SCHEMBL2623668 | 0.79 | DHODH (0.36) | MALT1DHODHTRPV1TRPA1ALDH1A1 | |
| SCHEMBL10136638 | 0.79 | SLC2A1 (0.33) | MALT1DHODHTRPV1 | |
| SCHEMBL45109 | 0.78 | MALT1 (0.38) | MALT1DHODHTRPA1RBP4ALDH1A1 | |
| SCHEMBL44964 | 0.77 | DHODH (0.34) | MALT1DHODHTRPV1TRPA1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582688-B1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-8791139-B2 | Anthranilic diamide derivatives | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2582688-A1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2013-04-24 | — | — | EP | disclosed |
| US-20120015980-A1 | ANTHRANILIC DIAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2012-01-19 | — | — | US | disclosed |
| WO-2011157654-A1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015980-A1 | ANTHRANILIC DIAMIDE DERIVATIVES | DDT, QDPR, ANTXR2 | MALT1 4605/4885DHODH 197/4885TRPV1 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.